Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | CCR7 | P32248 | 2/20 | 0.38 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14214648 | 0.87 | CXCR2 (0.50) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL14214579 | 0.87 | CXCR2 (0.47) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL14214577 | 0.86 | CXCR2 (0.43) | CXCR2CXCR1CCR7CX3CR1RAB9A | |
| SCHEMBL3611708 | 0.85 | CXCR2 (0.52) | CXCR2CX3CR1 | |
| SCHEMBL14214650 | 0.82 | CXCR2 (0.51) | CXCR2CXCR1CCR7NPC1RAB9A | |
| SCHEMBL14214649 | 0.80 | CXCR2 (0.39) | CXCR2CXCR1CCR7 | |
| SCHEMBL14214570 | 0.80 | CXCR2 (0.42) | CXCR2CXCR1CCR7CX3CR1 | |
| SCHEMBL14214572 | 0.79 | CXCR2 (0.43) | CXCR2CXCR1CCR7NPC1RAB9A | |
| SCHEMBL14214574 | 0.76 | ADORA2A (0.45) | CXCR2CXCR1CCR7NPC1HPGD | |
| SCHEMBL14214462 | 0.74 | CXCR2 (0.47) | CXCR2CXCR1CCR7CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008061740-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |